Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
3677285011 | Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3677286012 | Product containing precisely carbidopa 12.5 milligram and entacapone 200 milligram and levodopa 50 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Is a | Product containing carbidopa and entacapone and levodopa (medicinal product) | false | Inferred relationship | Some | ||
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has active ingredient | Entacapone (substance) | false | Inferred relationship | Some | ||
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has active ingredient | Levodopa (substance) | false | Inferred relationship | Some | ||
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has active ingredient | Carbidopa | false | Inferred relationship | Some | ||
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has manufactured dose form | Tablet | false | Inferred relationship | Some | ||
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Is a | Product manufactured as oral dose form (product) | false | Inferred relationship | Some | ||
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 1 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has basis of strength substance (attribute) | Levodopa (substance) | true | Inferred relationship | Some | 2 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength numerator value | 50 | false | Inferred relationship | Some | 2 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 2 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has active ingredient | Entacapone (substance) | false | Inferred relationship | Some | 3 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has basis of strength substance (attribute) | Entacapone (substance) | false | Inferred relationship | Some | 3 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength numerator value | 200 | false | Inferred relationship | Some | 3 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 3 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 3 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 3 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has basis of strength substance (attribute) | Entacapone (substance) | true | Inferred relationship | Some | 1 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength numerator value | 200 | false | Inferred relationship | Some | 1 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has basis of strength substance (attribute) | Carbidopa | true | Inferred relationship | Some | 3 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength numerator value | 12.5 | false | Inferred relationship | Some | 3 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has active ingredient | Levodopa (substance) | false | Inferred relationship | Some | 1 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has basis of strength substance (attribute) | Levodopa (substance) | false | Inferred relationship | Some | 1 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength numerator value | 50 | false | Inferred relationship | Some | 1 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has active ingredient | Carbidopa | false | Inferred relationship | Some | 2 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has basis of strength substance (attribute) | Carbidopa | false | Inferred relationship | Some | 2 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has presentation strength numerator value | 12.5 | false | Inferred relationship | Some | 2 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has precise active ingredient | Carbidopa | true | Inferred relationship | Some | 3 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Is a | Product containing carbidopa and entacapone and levodopa in oral dose form (medicinal product form) | false | Inferred relationship | Some | ||
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has precise active ingredient | Entacapone (substance) | true | Inferred relationship | Some | 1 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Has precise active ingredient | Levodopa (substance) | true | Inferred relationship | Some | 2 | |
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Count of base of active ingredient | 3 | false | Inferred relationship | Some | ||
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Is a | Product containing only carbidopa and entacapone and levodopa in oral dose form (medicinal product form) | true | Inferred relationship | Some | ||
Carbidopa 12.5 mg and entacapone 200 mg and levodopa 50 mg oral tablet | Plays role | Antiparkinson therapeutic role | false | Inferred relationship | Some |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Description inactivation indicator reference set